Gufic Biosciences Limited (BOM: 509079)
India
· Delayed Price · Currency is INR 408.15
+15.75 (4.01%)
At close: Oct 11, 2024
Gufic Biosciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Revenue | 8,145 | 8,067 | 6,906 | 7,792 | 4,877 | 3,788 | Upgrade
|
| Revenue Growth (YoY) | 13.06% | 16.80% | -11.36% | 59.76% | 28.74% | 8.00% | Upgrade
|
| Cost of Revenue | 3,878 | 3,986 | 3,393 | 4,207 | 2,565 | 1,850 | Upgrade
|
| Gross Profit | 4,267 | 4,080 | 3,513 | 3,585 | 2,312 | 1,938 | Upgrade
|
| Selling, General & Admin | 1,153 | 1,132 | 940.25 | 913.47 | 691.2 | 637.3 | Upgrade
|
| Other Operating Expenses | 1,652 | 1,466 | 1,197 | 1,191 | 781.26 | 776.65 | Upgrade
|
| Operating Expenses | 2,976 | 2,769 | 2,360 | 2,294 | 1,635 | 1,553 | Upgrade
|
| Operating Income | 1,291 | 1,312 | 1,153 | 1,291 | 676.53 | 385.4 | Upgrade
|
| Interest Expense | -159.11 | -145.64 | -66.36 | -40.06 | -117.66 | -126.79 | Upgrade
|
| Interest & Investment Income | - | 14.13 | 14.13 | 18.8 | 14.51 | 13.64 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 4.97 | -29.61 | 6.93 | 14.34 | -2.62 | Upgrade
|
| Other Non Operating Income (Expenses) | 25.51 | -5.28 | -4.56 | -8.97 | -10.77 | 31.43 | Upgrade
|
| EBT Excluding Unusual Items | 1,157 | 1,180 | 1,067 | 1,268 | 576.95 | 301.06 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -0.21 | -0.01 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -23 | 0.3 | 0.68 | 0.37 | 0.21 | Upgrade
|
| Pretax Income | 1,157 | 1,157 | 1,067 | 1,268 | 577.12 | 301.26 | Upgrade
|
| Income Tax Expense | 293.58 | 295.36 | 270.16 | 309.98 | 134.8 | 74.38 | Upgrade
|
| Net Income | 863.69 | 861.36 | 797.05 | 958.4 | 442.32 | 226.88 | Upgrade
|
| Net Income to Common | 863.69 | 861.36 | 797.05 | 958.4 | 442.32 | 226.88 | Upgrade
|
| Net Income Growth | 8.95% | 8.07% | -16.84% | 116.68% | 94.96% | 3.41% | Upgrade
|
| Shares Outstanding (Basic) | 99 | 99 | 97 | 97 | 97 | 78 | Upgrade
|
| Shares Outstanding (Diluted) | 99 | 99 | 97 | 97 | 97 | 78 | Upgrade
|
| Shares Change (YoY) | 2.60% | 1.63% | - | - | 24.56% | - | Upgrade
|
| EPS (Basic) | 8.69 | 8.74 | 8.22 | 9.89 | 4.56 | 2.92 | Upgrade
|
| EPS (Diluted) | 8.69 | 8.74 | 8.22 | 9.89 | 4.56 | 2.92 | Upgrade
|
| EPS Growth | 6.21% | 6.33% | -16.85% | 116.80% | 56.43% | 3.41% | Upgrade
|
| Free Cash Flow | - | -1,202 | -2,142 | 187.86 | 748.52 | 72.52 | Upgrade
|
| Free Cash Flow Per Share | - | -12.20 | -22.09 | 1.94 | 7.72 | 0.93 | Upgrade
|
| Dividend Per Share | - | 0.100 | 0.100 | 0.100 | 0.100 | 0.050 | Upgrade
|
| Dividend Growth | - | 0% | 0% | 0% | 100.00% | 0% | Upgrade
|
| Gross Margin | 52.39% | 50.58% | 50.87% | 46.01% | 47.40% | 51.16% | Upgrade
|
| Operating Margin | 15.85% | 16.26% | 16.70% | 16.57% | 13.87% | 10.17% | Upgrade
|
| Profit Margin | 10.60% | 10.68% | 11.54% | 12.30% | 9.07% | 5.99% | Upgrade
|
| Free Cash Flow Margin | - | -14.89% | -31.01% | 2.41% | 15.35% | 1.91% | Upgrade
|
| EBITDA | 1,465 | 1,408 | 1,307 | 1,430 | 803.85 | 494.06 | Upgrade
|
| EBITDA Margin | 17.99% | 17.45% | 18.92% | 18.36% | 16.48% | 13.04% | Upgrade
|
| D&A For EBITDA | 174.36 | 96.33 | 153.43 | 139.3 | 127.32 | 108.66 | Upgrade
|
| EBIT | 1,291 | 1,312 | 1,153 | 1,291 | 676.53 | 385.4 | Upgrade
|
| EBIT Margin | 15.85% | 16.26% | 16.70% | 16.57% | 13.87% | 10.17% | Upgrade
|
| Effective Tax Rate | 25.37% | 25.53% | 25.31% | 24.44% | 23.36% | 24.69% | Upgrade
|
| Revenue as Reported | 8,170 | 8,088 | 6,932 | 7,823 | 4,914 | 3,846 | Upgrade
|
| Advertising Expenses | - | 21.23 | 59.56 | 33.44 | 18.57 | 37.07 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.